175 related articles for article (PubMed ID: 37429084)
1. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Amin SA; Khatun S; Gayen S; Das S; Jha T
Eur J Med Chem; 2023 Oct; 258():115594. PubMed ID: 37429084
[TBL] [Abstract][Full Text] [Related]
2. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
[TBL] [Abstract][Full Text] [Related]
3. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
5. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
6. HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia.
Spreafico M; Gruszka AM; Valli D; Mazzola M; Deflorian G; Quintè A; Totaro MG; Battaglia C; Alcalay M; Marozzi A; Pistocchi A
Front Cell Dev Biol; 2020; 8():844. PubMed ID: 33015043
[TBL] [Abstract][Full Text] [Related]
7. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
10. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
11. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Zhang P; Brinton LT; Williams K; Sher S; Orwick S; Tzung-Huei L; Mims AS; Coss CC; Kulp SK; Youssef Y; Chan WK; Mitchell S; Mustonen A; Cannon M; Phillips H; Lehman AM; Kauffman T; Beaver L; Canfield D; Grieselhuber NR; Alinari L; Sampath D; Yan P; Byrd JC; Blachly JS; Lapalombella R
Clin Cancer Res; 2021 Apr; 27(8):2352-2366. PubMed ID: 33542077
[TBL] [Abstract][Full Text] [Related]
15. Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties.
Sun P; Wang J; Khan KS; Yang W; Ng BW; Ilment N; Zessin M; Bülbül EF; Robaa D; Erdmann F; Schmidt M; Romier C; Schutkowski M; Cheng AS; Sippl W
J Med Chem; 2022 Dec; 65(24):16313-16337. PubMed ID: 36449385
[TBL] [Abstract][Full Text] [Related]
16. HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.
Wu J; Zhang L; Feng Y; Khadka B; Fang Z; Liu J
Biol Chem; 2021 Mar; 402(4):461-468. PubMed ID: 33938176
[TBL] [Abstract][Full Text] [Related]
17. Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents.
Sonnemann J; Gruhn B; Wittig S; Becker S; Beck JF
Br J Haematol; 2012 Sep; 158(5):664-6. PubMed ID: 22686282
[No Abstract] [Full Text] [Related]
18. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
19. Kinetically selective and potent inhibitors of HDAC8.
Schweipert M; Jänsch N; Sugiarto WO; Meyer-Almes FJ
Biol Chem; 2019 May; 400(6):733-743. PubMed ID: 30521473
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of histone deacetylase-8 in human breast cancer.
Rahmani G; Sameri S; Abbasi N; Abdi M; Najafi R
Pathol Res Pract; 2021 Apr; 220():153396. PubMed ID: 33691240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
